TABLE 2

Characteristics of Patients With the Most Frequent MSKDs Among the MSKD+ Population

FS+(n = 19 [47.5%])Tendinitis+*(n = 15 [37.5%])CTS+(n = 13 [32.5%])TF+(n = 12 [30.0%])
Age, years54.1 ± 9.249.1 ± 11.356.2 ± 8.355.9 ± 8.4
Diabetes duration, years31.8 ± 12.828.5 ± 9.733.9 ± 8.633.9 ± 7.9
Age at diabetes diagnosis, years22.3 ± 10.520.6 ± 9.522.3 ± 10.422.0 ± 9.2
BMI, kg/m227.0 ± 3.928.5 ± 4.429.0 ± 3.726.3 ± 4.1
Mean A1C, %7.7 ± 1.77.3 ± 1.07.7 ± 1.17.5 ± 0.9
Men/women7/12 (37/61)8/7 (53/47)5/8 (38/62)3/9 (25/74)
≥1 Complication12 (63.2)10 (66.7)11 (84.6)9 (75.0)
Diabetic retinopathy12 (63.2)10 (66.7)11 (84.6)9 (75.0)
Diabetic nephropathy2 (10.5)1 (6.7)2 (15.4)1 (8.3)
Diabetic neuropathy3 (15.8)1 (6.7)2 (15.4)1 (8.3)
CVD2 (10.5)4 (26.7)5 (38.5)4 (33.3)
Smoking status
Current smokers2 (10.5)2 (13.3)00
Former smokers5 (26.3)3 (20.0)5 (38.5)5 (41.7)
Never smokers12 (63.2)10 (66.7)8 (61.5)7 (58.3)
Age at first MSKD diagnosis, years48.5 ± 9.844.5 ± 11.849.7 ± 9.549.0 ± 8.0
1 MSKD10 (52.6)5 (33.3)1 (7.7)3 (25.0)
2+ MSKD9 (47.4)10 (66.7)12 (92.3)9 (75.0)
MSKD components
FS19 (100.0)5 (33.3)5 (38.5)4 (33.3)
Tendinitis*5 (26.3)15 (100.0)6 (46.2)5 (41.7)
CTS5 (26.3)6 (40.0)13 (100.0)5 (41.7)
TF4 (21.1)5 (33.3)5 (38.5)12 (100.0)
Epicondylitis3 (15.8)4 (26.7)4 (30.8)5 (41.7)
DD3 (15.8)2 (13.3)1 (7.7)2 (16.7)
Morton’s neuroma1 (5.3)1 (6.7)3 (23.1)1 (8.3)
de Quervain’s tenosynovitis1 (5.3)1 (6.7)1 (7.7)1 (8.3)
Ulnar tunnel syndrome1 (5.3)1 (6.7)1 (7.7)1 (8.3)
  • Data are mean ± SD or n (%). CSII, continuous subcutaneous insulin infusion; CTS+, history of CTS; FS+, history of FS; MDI, multiple daily injections; TF+, history of TF.

  • * Shoulder tendinitis (n = 10), wrist tendinitis (n = 3), hip or knee tendinitis (n = 2).

  • Mean of the last three values available.

  • Medial or lateral epicondylitis.